Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the
1Memorial Sloan Kettering Cancer Center, New York, United States.
Future Oncology (London, England)
|January 9, 2025
Abstract
No abstract available in PubMed .
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.5K
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
1.9K
